CE-355621
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibits the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
|
c-Met |
CE-355621 (0.01-100 nM, 4 h) can efficiently block the binding of c-Met to HGF and induce c-Met degradation in A549 cells[1].
CE-355621 (0.01 nM-10 nM, 24 h) significantly inhibits c-Met activation in U87MG cells[1].
CE-355621 (0.01-10 μg/mL, 48 h) can induce c-Met degradation in U87MG cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CE-355621 (400 μg, i.p., on day 7 and 14) significantly inhibits tumor growth in female CD-1 nu/nu mice bearing GTL-16 xenografts[1].
CE-355621 (200 μg, i.p., single dose, on day 7) can effectively inhibit tumor volume growth and uptake of 18F-FDG in female nude (nu/nu) mice bearing U87MG xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×106 U87MG cells injected female CD-1 nu/nu mice[1]
-
Dosage:25, 100 and 200 μg
-
Administration:Intraperitoneal injection (i.p.) on day 0, 2, 3, 6 and 8
-
Result:Significantly delayed tumor growth (up to 22.3 days) and inhibited 80 % of c-Met phosphorylation.
-
Animal Model:1.0-5.0×106 GTL-16 cells injected female CD-1 nu/nu mice[1]
-
Dosage:400 μg
-
Administration:Intraperitoneal injection (i.p.) on day 7 and 14
-
Result:Inhibited tumor growth by 85% and reduced c-Met phosphorylation by 48%.
-
Animal Model:1×106 U87MG cells injected female nude (nu/nu) mice[2]
-
Dosage:200 μg
-
Administration:Intraperitoneal injection (i.p.), single dose on day 7
-
Result:Significantly inhibited tumor volume.
Significantly reduced uptake of 18F-FDG.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Michaud NR, et al. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. MAbs. 2012 Nov-Dec;4(6):710-23. [Content Brief]
[2]. Tseng JR, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 2008 Jan;49(1):129-134. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CE-355621 Related Classifications
HY-P991565 Related Classifications
Powered by Bioz